Pfizer Near Resolution Of GMP Warning Letter; Lilly, Merck Provide Updates
Executive Summary
Pfizer expects a re-inspection of its Terre Haute, Ind. injectable manufacturing facility before the end of the month, the company told investors during an April 17 conference call
You may also be interested in...
Pfizer Vfend Antifungal Has Broader Indication, Doses Than Merck’s Cancidas
Pfizer's Vfend has a broader indication and more dosing options than Merck's Cancidas upon FDA approval of the Pfizer antifungal
Pfizer Vfend Antifungal Has Broader Indication, Doses Than Merck’s Cancidas
Pfizer's Vfend has a broader indication and more dosing options than Merck's Cancidas upon FDA approval of the Pfizer antifungal
GMP Compliance Guidances Should Be Increased, Lilly’s Miner Says
FDA needs to issue more guidances on GMP compliance topics, Lilly Corporate GMP Compliance Leader David Miner, PhD, said